Octapharma (Switzerland)

Octapharma (Switzerland)

Octapharma AG, founded in 1983, is a family-owned pharmaceutical company based in Switzerland. It bills itself as "one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines." Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Octapharma (Switzerland), Switzerland, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

43%


Total
Publications

328


Total Open
Publications

140


Total
Citations

5.4K


Open Access
Percentage

43%


Total
Publications

328


Total Open
Publications

140


Total
Citations

5.4K

Wikipedia

Website

download

Breakdown

21% 18% 4% 57%

Publisher Open

21%

Both

18%

Other Platform Open

4%

Closed

57%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02468101214161820222426Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

22%OA Journal

OA Journal 22%

28

Hybrid 39%

49

No Guarantees 39%

50

Other Platform Open

Domain 79%

58

Institution 32%

23

Public 12%

9

Other Internet 8%

6

Preprint 4%

3

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
58
Europe PMC
Domain
38
Semantic Scholar
Public
7
Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca
Institution
4
Erasmus University Rotterdam - EUR Research Repository
Institution
4
University of California - eScholarship University of California
Institution
3
Le Centre pour la Communication Scientifique Directe - HAL - memSIC
Other Internet
3
University of Southampton - ePrints Soton
Institution
2
University of Michigan - Deep Blue
Institution
2
Open Research Library
Public
2
1 / 3

Data updated 17 June 2024

Share

Share

Share